LONDON and MILAN, Nov. 03, 2025(AAVantgarde), a clinical-stage, biotechnology company pioneering therapies for inherited retinal diseases (IRDs), today announced the successful closing of a $141 milli ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback